Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
JGH Open · 2023-09 · 7 (9) · 659-666
DOI: 10.1002/jgh3.12966 ↗Kurz gefasst
Fachartikel in der Zeitschrift JGH Open, online erschienen am 07.09.2023. Verfasst von Ken Kamata und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology Kindai University Faculty of Medicine Osaka Japan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Research Foundation for Clinical Pharmacology.
Abstract (Originalsprache)
Background and Aim A multicenter, open‐label randomized Phase II trial was conducted to determine whether low‐dose gemcitabine plus nab‐paclitaxel (GnP) could improve tolerability and show equivalent efficacy to the standard‐dose GnP for elderly patients with metastatic pancreatic cancer.
Methods
Consecutive patients aged ≥65 years with metastatic pancreatic cancer who presented at one of four Japanese referral centers between November 2016 and January 2021 were enrolled. The 60 patients were randomly assigned to low‐ or standard‐dose groups with a 1:1 ratio. Patients in the low‐dose GnP group received gemcitabine at a dose of 250 mg/m 2 and nab‐paclitaxel at 125 mg/m 2 .
Results
Low‐dose GnP significantly decreased the rate of cases requiring dose reduction (16.7% vs 63.3%). The response rate (36.7% vs 33.3%) and progression‐free survival (7.3 vs 8 months) were comparable between the low‐ and standard‐dose groups as determined by independent review. The difference in the median overall survival between the two groups was not significant (7.9 vs 12 months). The proportion of patients with hematologic and non‐hematologic treatment‐related adverse events was comparable between the two groups.
Conclusion
Low‐dose GnP had an equivalent efficacy to conventional therapy; however, it did not reduce adverse events.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology Kindai University Faculty of Medicine Osaka Japan.
- Department of Gastroenterology Okanami General Hospital Mie Japan.
- Department of Gastroenterology Japanese Red Cross Wakayama Medical Center Wakayama Japan.
- Department of Gastroenterology Hyogo Prefectural Awaji Medical Center Hyogo Japan.
- Department of Radiology Kindai University Faculty of Medicine Osaka-Sayama Japan.
- Clinical Research Center Kindai University Hospital Osaka Japan.
ORCID-Profile: Ken Kamata, Shunsuke Omoto, Kosuke Minaga, Tomohiro Watanabe, Masayuki Kitano
Förderung
- Japan Research Foundation for Clinical Pharmacology
Zitieren
APA
Kamata, K., Imai, H., Matsumoto, H., Yamashita, Y., Kato, T., Nishi, K., Omoto, S., Minaga, K., Yamao, K., Hyodo, T., Im, S. W., Hara, A., Yoshikawa, T., Ishikawa, R., Okamoto, A., Yamazaki, T., Nakai, A., Ueshima, K., Chiba, Y., …, & Kudo, M. (2023). Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial. JGH Open, 7(9), 659-666. https://doi.org/10.1002/jgh3.12966
Vancouver
Kamata K, Imai H, Matsumoto H, Yamashita Y, Kato T, Nishi K, et al. Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial. JGH Open. 2023;7(9):659-666. doi:10.1002/jgh3.12966
BibTeX
@article{Kamata2023,
author = {Kamata, Ken and Imai, Hajime and Matsumoto, Hisakazu and Yamashita, Yukitaka and Kato, Takao and Nishi, Katsuhisa and Omoto, Shunsuke and Minaga, Kosuke and Yamao, Kentaro and Hyodo, Tomoko and Im, Sung-Woon and Hara, Akane and Yoshikawa, Tomoe and Ishikawa, Rei and Okamoto, Ayana and Yamazaki, Tomohiro and Nakai, Atsushi and Ueshima, Kazuomi and Chiba, Yasutaka and Takenaka, Mamoru and Watanabe, Tomohiro and Kitano, Masayuki and Kudo, Masatoshi},
title = {Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial},
journal = {JGH Open},
year = {2023},
volume = {7},
number = {9},
pages = {659--666},
doi = {10.1002/jgh3.12966}
}
EUVIMED